Article
Targeting TPO/MPL Signaling to Mitigate JAK2V617F-driven Cardiac Microvascular Disease
2026-04-03
Abstract excerpt
<h4>Background</h4> Individuals with JAK2V617F -mutant myeloproliferative neoplasms or clonal hematopoiesis of indeterminate potential have a markedly increased risk of cardiovascular disease, yet the mechanisms by which mutant blood cells drive vascular and cardiac dysfunction remain incompletely understood. Although the thrombopoietin (TPO) receptor MPL is central to hematopoiesis and is expressed in vascular...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a2156a4d-f599-5461-b0af-f275ae77542a
- DOI
- 10.64898/2026.04.01.715884
